CJC-1295 No DAC & Ipamorelin

Ipamorelin

This peptide represents one of the most highly selective GH secretagogues available and demonstrates powerful agonist activity at the ghrelin/growth hormone secretagogue receptor. Multiple research studies have established its ability to strengthen bones, facilitate muscle tissue repair and growth, stimulate insulin production in pancreatic tissue, and enhance intestinal motility along with gastric function.

CJC-1295

This compound induces GH secretion through activation of the growth hormone releasing hormone receptor, employing a mechanism distinct from Ipamorelin. Its selectivity has been well-documented, with research revealing beneficial impacts on skeletal health, body composition favoring lean tissue, insulin response efficiency, and muscle tissue development. Combining these peptides may produce amplified benefits since they influence GH regulation through different receptor systems. Research with animal subjects using both compounds simultaneously suggests the possibility of enhanced efficacy without proportionally increased adverse effects.

The mechanism underlying their synergy involves Ipamorelin raising the baseline GH concentration, which allows CJC-1295 to achieve both higher peak values and elevated trough levels while maintaining the natural rhythmic pattern of GH secretion. This combination effectively raises the homeostatic set point for GH fluctuations, resulting in improved body composition, enhanced muscular development, optimized insulin function, and overall metabolic improvements.

Documentation Author

The research literature above was compiled, edited, and structured by Dr. E. Logan, M.D. Dr. Logan received a medical degree from Case Western Reserve University School of Medicine and holds a Bachelor of Science in molecular biology.

Scientific Contributor

Dr. Dominique Bridon obtained his Master of Science in Chemical Engineering and Polymer Sciences from École Nationale Supérieure de Chimie and completed his doctoral degree in Organic Chemistry at the University of Paris XI, ICSN, Orsay, France, working under Nobel Laureate Sir Derek H. R. Barton. He conducted postdoctoral research at the University of California, Berkeley. His research focused on CJC-1295 as a prolonged-action GRF analog, and he has held various executive and leadership roles in peptide research and technology development at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Board Director for Enobia (later acquired by Alexion) and Neuronax, and as a Scientific Advisory Board member for Syntaxin (later acquired by Ipsen) and Biosortia. He currently brings 30 years of combined scientific and executive leadership experience to Epivax Oncology.

Dr. Dominique Bridon is cited as one of the principal scientists involved in CJC-1295 research and development. This citation does not represent any endorsement or recommendation by this scientist for purchasing, selling, or using this product. No relationship, whether explicit or implied, exists between Peptide Sciences and this scientist. The citation's purpose is to recognize and credit the comprehensive research and development work conducted by scientists studying this peptide. Dr. Dominique Bridon appears in reference [10] in the citation list.

Citations

1. K. Raun et al., "Ipamorelin, the first selective growth hormone secretagogue," Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]
2. N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats," Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
3. J. Svensson et al., "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats," J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
4. E. Adeghate and A. S. Ponery, "Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats," Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
5. D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients," Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]
6. B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, "Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus," J. Exp. Pharmacol., vol. 4, pp. 149–165, Oct. 2012. [PubMed]
7. M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse," Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]
8. M. Ionescu and L. A. Frohman, "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog," J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]
9. M. C. Van Hout and E. Hearne, "Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions," Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]
10. Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]